Portfolio Company · Operating Co.

AKEURA (fka P95 Julius Clinical)

Pharma Services

backed byAmpersand Capital Partners

CurrentPharma Services

a portfolio company of

Ampersand Capital Partners

Status on record: Current

PE Firm Index

Who owns AKEURA (fka P95 Julius Clinical)?

AKEURA (fka P95 Julius Clinical) is listed as a current portfolio company of Ampersand Capital Partners on Ampersand Capital Partners' own portfolio page.

Company Snapshot

AKEURA (fka P95 Julius Clinical) is a Pharma Services company. Its owner on record, Ampersand Capital Partners, is a firm. Ampersand Capital Partners lists at least 68 companies in the index, 7 of them in Pharma Services.

SectorPharma Services

Parent PE firmAmpersand Capital Partners

Ownership statusCurrent

WebsiteNot on record

About the owner

Ampersand Capital Partners

Companies in the index: At least 68

Read the Ampersand Capital Partners profile

Questions about AKEURA (fka P95 Julius Clinical)

Who owns AKEURA (fka P95 Julius Clinical)?

AKEURA (fka P95 Julius Clinical) is listed as a current portfolio company of Ampersand Capital Partners on Ampersand Capital Partners' own portfolio page.

What sector is AKEURA (fka P95 Julius Clinical) in?

AKEURA (fka P95 Julius Clinical) is in Pharma Services. Classified from the owner's portfolio label.

What else does Ampersand Capital Partners own in Pharma Services?

Ampersand Capital Partners lists 6 other Pharma Services companies in the index, including Beacon Intelligence, BioClinica, CRI Lifetree, iuvo and Lexington Medical.

Sources

Ampersand Capital Partners
https://ampersandcapital.com/portfolio/

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with AKEURA (fka P95 Julius Clinical) and does not provide investment advice.

Other portfolio companies of Ampersand Capital Partners

6 of 67 shown

Contract Manufacturing

See the full Ampersand Capital Partners portfolio.

Other Pharma Services companies held by Ampersand Capital Partners

Beacon Intelligence BioClinica CRI Lifetree iuvo Lexington Medical Recipharm

Other Pharma Services portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Ampersand Capital Partners

Status: Current

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.